Last Updated: November 8, 2026

Patent: 10,214,586

Summary for Patent: 10,214,586

Title:	PD-L1 antibodies
Abstract:	The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
Inventor(s):	Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
Assignee:	Eli Lilly and Co
Application Number:	US15/239,959
Patent Claims:	see list of patent claims

Details for Patent 10,214,586

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Suspension	125736	March 3, 2021	⤷ Start Trial	2036-08-18
Celgene Corporation, A Bristol-myers Squibb Company	ABECMA	idecabtagene vicleucel	Suspension	125736	April 4, 2024	⤷ Start Trial	2036-08-18
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769	May 31, 2023	⤷ Start Trial	2036-08-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,214,586

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Argentina	105654	⤷ Start Trial
Australia	2016313404	⤷ Start Trial
Brazil	112018001506	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.